SGC0946 TFA is a selective inhibitor of DOT1L with an IC50 value of 0.3 nM. It induces G1 phase arrest in cancer cells by inhibiting DOT1L and reduces cellular self-renewal and metastatic potential while promoting cell differentiation. SGC0946 TFA is applicable in research for tumors such as leukemia and breast cancer and serves as a probe for studying the cellular mechanisms of DOT1L in both normal and diseased cells.
Target-Kategorie:
Histone Methyltransferase
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
